메뉴 건너뛰기




Volumn 54, Issue , 2012, Pages S77-S81

Use of apomorphine in patients with Parkinson’s disease;Utilización de apomorfina en el paciente con enfermedad de Parkinson

Author keywords

Apomorphine; Continuous infusion; Dopamine agonist; Fluctuations; Intermittent injections; Parkinson

Indexed keywords

APOMORPHINE;

EID: 84940291946     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (2)

References (11)
  • 3
    • 0021142576 scopus 로고
    • On-off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study
    • Jun
    • Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain. 1984 Jun;107 (Pt 2):487-506
    • (1984) Brain , vol.107 , pp. 487-506
    • Hardie, R.J.1    Lees, A.J.2    Stern, G.M.3
  • 4
    • 0018746617 scopus 로고
    • Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease
    • Corsini GU, Del Zompo M, Gessa GL, et al. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1979;i:954-6.
    • (1979) Lancet , vol.1 , pp. 954-956
    • Corsini, G.U.1    Del Zompo, M.2    Gessa, G.L.3
  • 5
    • 0028798114 scopus 로고
    • Peripheral and central pharmacokinetics of apomorphine and its effects on dopamine metabolism in humans
    • Przedborski S, Levivier M, Raftopoulos C, et al. Peripheral and central pharmacokinetics of apomorphine and its effects on dopamine metabolism in humans. Mov Disord 1995;10:28-36.
    • (1995) Mov Disord , vol.10 , pp. 28-36
    • Przedborski, S.1    Levivier, M.2    Raftopoulos, C.3
  • 8
    • 61449143704 scopus 로고    scopus 로고
    • Ultrasound treatment of cutaneous side-effects of infused apomorphine: A randomized controlled pilot study
    • Jan 15
    • Poltawski L, Edwards H, Todd A, Watson T, Lees A, James CA. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov Disord. 2009 Jan 15;24(1):115-8
    • (2009) Mov Disord , vol.24 , Issue.1 , pp. 115-118
    • Poltawski, L.1    Edwards, H.2    Todd, A.3    Watson, T.4    Lees, A.5    James, C.A.6
  • 9
    • 0028830804 scopus 로고
    • Apomorphine infusional therapy in Parkinson’s disease: Clinical utility and lack of tolerance
    • Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord 1995; 10: 34-43.
    • (1995) Mov Disord , vol.10 , pp. 34-43
    • Gancher, S.T.1    Nutt, J.G.2    Woodward, W.R.3
  • 10
    • 0031765885 scopus 로고    scopus 로고
    • Subcutaneous apomorphine in late stage Parkinson’s disease: A long term follow up
    • Nov
    • Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):709-16.
    • (1998) J Neurol Neurosurg Psychiatry , vol.65 , Issue.5 , pp. 709-716
    • Pietz, K.1    Hagell, P.2    Odin, P.3
  • 11
    • 0027264828 scopus 로고
    • Subcutaneous apomorphine in Parkinson’s disease: Response to chronic administration for up to five years
    • Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-70.
    • (1993) Mov Disord , vol.8 , pp. 165-170
    • Hughes, A.J.1    Bishop, S.2    Kleedorfer, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.